checkAd

EQS-News Relief Reports that NeuroRx has Announced that Aviptadil has been Selected for Inclusion in NIH-Sponsored Global Clinical Trial which Includes Aviptadil and Remdesivir

Nachrichtenquelle: EQS Group AG
07.04.2021, 07:00  |  123   |   |   

EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study
Relief Reports that NeuroRx has Announced that Aviptadil has been Selected for Inclusion in NIH-Sponsored Global Clinical Trial which Includes Aviptadil and Remdesivir

07.04.2021 / 07:00


Relief Reports that NeuroRx has Announced that Aviptadil has been Selected for Inclusion in NIH-Sponsored Global Clinical Trial which Includes Aviptadil and Remdesivir

Geneva, Switzerland, April 07, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development, announces that NeuroRx, Inc. has reported that aviptadil has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries. The trial, designated as TESICO (Therapeutics for Severely Ill Inpatients with COVID-19), is funded by the U.S. Government COVID-19 Therapeutics Response and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).

The relevant NeuroRx press release can be found here:

###

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.

Seite 1 von 3


RELIEF THERAPEUTICS Holding Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

EQS-News Relief Reports that NeuroRx has Announced that Aviptadil has been Selected for Inclusion in NIH-Sponsored Global Clinical Trial which Includes Aviptadil and Remdesivir EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study Relief Reports that NeuroRx has Announced that Aviptadil has been Selected for Inclusion in NIH-Sponsored Global Clinical Trial which Includes Aviptadil and Remdesivir 07.04.2021 …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

ZeitTitel
17.05.21
17.05.21
17.05.21
04.05.21
04.05.21
04.05.21
22.04.21
22.04.21
19.04.21
19.04.21